



Genetically Modified Stem Cells For The Treatment Of Insulin Deficiency In Diabetes

Huda Yassir Aswad, Shahd Abdulamer Kadhim and Zahraa Ali Jassim

College of medicine, Al-Muthanna University

Article Information

Received: 27-7-2026

Accepted: 1-9-2026

Published: 1-10-2026

Abstract

Core Objective: The strategy aims to transition from the lifelong, symptomatic management of diabetes (via external insulin injections) to a functional biological cure by replacing destroyed or exhausted pancreatic beta cells. **Stem Cell Source:** Scientists utilize embryonic stem cells or induced pluripotent stem cells (iPSCs), directing them in a laboratory setting to differentiate into functional, glucose-responsive, insulin-secreting cells. **Genetic Engineering Solutions:** Advanced gene-editing tools (such as CRISPR) are applied to the stem cells prior to transplantation to address key medical barriers: **Immune Evasion:** Modifying cells to hide from or resist the host's immune system, eliminating the need for toxic, lifelong systemic immunosuppressants. **Enhanced Viability:** Engineering cells to promote rapid blood vessel growth and survive the hypoxic stress immediately following transplantation. **Remaining Obstacles:** Key challenges include managing the theoretical risk of tumor formation from undifferentiated cells, overcoming high manufacturing and scalability costs, and confirming long-term safety through rigorous clinical trials.

Keywords: diabetes, Stem Cell, Genetic, Insulin.

Introduction

Diabetes has been among the most acute international health problems, and the prevalence, economic burdens, and harsh long-term complications remain to be mitigated in healthcare systems across the globe. Despite the slight evolution of insulin preparations, glucose-monitoring tools, and insulin-insensitive pharmacological and pharmacological treatments, there is still no cure for the problem of insulin-deficient diabetes because the current treatment options are unable to solve the underlying cause of the condition, namely, permanent deficiency or dysfunction of insulin-producing pancreatic beta cells. The therapeutic potential of stem-cell-based therapies has turned out to be a ground-breaking one, as it poses the possibility

of restoring endogenous insulin regulation by regenerating functional 3-D cells capable of restoring insulin-like production (Zuo et al., 2025). However, naturally differentiated β cells of the stem cells are not completely mature, stable, or immune resistant.

Genetic modification brings in a strong aspect of optimization, which enhances 100 percent 2-cell growth, insulin synthesis, and survival after transplantation. Moreover, the growing scientific interest in stem-cell engineering points to the realization that cellular therapies must go beyond mere differentiation approaches to molecular reinforcement, with a view toward long-term clinical sustainability (Khunti et al., 2023). The paper's genetically modified stem cell thesis is the best and most advanced solution for long-term, glucose-sensitive insulin replacement in diabetic patients, addressing the limitations of current treatment options.

Problem Statement and Research Niche

Diabetes, especially Type 1 and Type 2 diabetes, which is advanced and insulin-deficient, is characterised by the inability of the body to produce adequate insulin due to destruction or failure of the β cell of the pancreas (9). Traditional management relies heavily on exogenous insulin administration, glucose monitoring, and lifetime glycemic control programs (Oliveira et al., 2023). Although these forms are the only way to remain alive, they do not mimic the complex, glucose-responsive insulin secretion that healthy beta cells normally provide. Lack of this physiological regulation causes the variability of blood glucose levels, which can put the individual at risk of hypoglycemia, hyperglycemia, as well as cumulative long-term impacts such as neuropathy, nephropathy, and cardiovascular disease.

There is still a critical research gap, as current 2-cell replacement therapies struggle to generate fully functional, durable, and immune-rejecting cells. Even in the instances of producing stem-cell-derived 8-like cells, a high proportion exhibit juvenile insulin-release phenotypes and poor resilience following transplantation (Oliveira et al., 2023). This highlights the necessity of genetic engineering methods that would enable fortification of the developmental, functional, and immunological features of stem-cell-produced 2 cells. In short, to enhance stem-cell resilience, further studies of the cell-microenvironment interface are needed, as transplanted cells are exposed to oxidative stress, inflammatory cytokines, and metabolic stress, which may lead to cell death even when differentiation quality is thought to be favorable.

Significance of Stem Cells in Diabetes Treatment

Stem cells are now the focus of efforts to restore the lost mass of the β -cells, as they can be instructed to become pancreatic endocrine cells. Embryonic stem cells and induced pluripotent stem cells are pluripotent stem cells that can differentiate into any cell type under the right conditions (Ghoneim et al., 2024). Thus, when directed along certain developmental pathways, these cells can give rise to populations resembling pancreatic progenitors and, eventually, insulin-producing β cells.

The main benefit of stem-cell-based treatments is their scalability. Stem-cell platforms have the potential to generate limitless numbers of therapeutic cells, unlike donor-island transplantation, which is plagued by inadequate tissue supply. Also, induced pluripotent stem cells offer an opportunity for patient-specific therapy that avoids alloimmune reactions. Nevertheless, unless genetic optimisation is performed, the resulting β -like cells often lack the structural and molecular features of mature human β cells (Jiang & Jiang, 2023). This has curtailed scientific interest in using genetic modification techniques to improve cell function and extend longevity. In addition, the ability of stem cells to become part of the systemic metabolic process has certain translational value, as a successful application would make diabetes management no longer a symptom-management approach but rather a biological repair process.

Why Genetic Modification is Critical in Enhancing Insulin Production

Genetic engineering is key to addressing the limitations of unmodified stem-cell-derived 2 cells. Some transcription factors play a crucial role in determining the 3-cell lineage, maturation, and glucose-responsive insulin secretion. The most affecting ones are PDX1, MAFA, and NKX6.1, which collectively coordinate pancreatic identity, insulin gene expression, and functional stability of 90s cells (Ghoneim et al., 2024). In the absence of altered differentiation protocols, the final outcome of β -like cells is insufficient expression of these factors, leading to poor insulin production and immature glucose responsiveness.

Through precise genetic modification—especially CRISPR-driven gene activation or targeted knock-in techniques—researchers can trigger expression of crucial developmental genes during strictly defined stages of cellular differentiation. Increasing PDX1 levels reinforces pancreatic lineage commitment and increases the expression of key pathways required for insulin production (Jiang & Jiang, 2023). Increased MAFA expression aids in 15/20-cell differentiation by enhancing glucose responsiveness and stabilising insulin release. Similarly, optimising NKX6.1 expression improves the identity of 2-2 cells and prevents premature dedifferentiation. All these changes result in cells that are better functional copies of pancreatic beta cells, more stable and with higher secretory capacity.

The CRISPR Gene Editing Role in Improving 8 Cell Function

CRISPR gene editing has revolutionised biomedical research, providing researchers with the opportunity to modify DNA with accuracy, efficiency, and precision, and to program it. In the context of β -cell replacement therapy, CRISPR provides an opportunity to target the improvement of critical regulatory genes or to add protective mutations that would increase the engineered cells' ability to survive after transplantation (Vaghari-Tabari et al., 2022). In addition to inducing 2C-cell development, gene editing can be used to reduce immunogenicity, increase resistance to autoimmune destruction, and add safety switches that make clinical applications safer.

CRISPR can be used to customise insulin-regulatory gene networks, to induce stem-cell-derived 2 cells to produce the molecular machinery needed to support physiological glucose sensing. In addition, CRISPR enables the deletion of molecules that cause immune rejection, e.g., specific HLA proteins, or the incorporation of immune-evasive molecules such as HLA-E or CD47 (Vaghari-Tabari et al., 2022). In this way, CRISPR not only increases insulin-production capacity but also contributes to the development of 3D-printed 3-cell sections that are more appropriate for transplantation into a wide variety of patients with diabetes, including those with autoimmune diabetes. CRISPR technologies also offer the possibility of multidimensional engineering, in which the metabolic operation, survival pathways, and invisibility to immunology can be improved simultaneously, which is likely to lead to clinical success.

Insulin Secretion from Modified Stem Cells in Improving Functionality

Stem-cell-derived β cells that are genetically modified have far better functional profiles than their non-modified counterparts. PDX1, MAFA, and NKX6.1 upregulation results in enhanced glucose-stimulated insulin secretion, a feature of healthy 8-cells. These man-made cells can generate insulin in a timely and regulated manner, closely resembling natural 8-cell rhythms (Zuo et al., 2025). This physiological responsiveness is necessary to prevent both hypo- and hyperglycemic excursions after transplantation.

Making adjustments to genes involved in insulin processing ensures that the insulin released is not only abundant but also properly folded and biologically active. There are also some genetic strategies that enhance the structural integrity of insulin-containing granules, resulting in stronger secretory performance (Oliveira et al., 2023). Together, these improvements render genetically modified β cells more appropriate

and viable for cell-replacement therapy in diabetes. Better granule production and stability also lead to a prolonged insulin release in times of metabolic demand, enhancing their reliability in therapy over long periods.

Solution to Problems: Immune Rejection and Cell Survival

The hostile immune environment to which transplanted cells are exposed is one of the biggest challenges in β -cell replacement therapy. In Type 1 diabetes, autoimmunity directly targets β -cells, whereas in all environments, alloimmune reactions jeopardise the appearance of donor-derived cells (Oliveira et al., 2023). This two-fold threat to the immune system has the potential to cause quick failure of the working β cells, even when the transplanted cells are optimised.

Genetic modification provides multiple sophisticated solutions that effectively address the problem. Modifications of the HLA can also cause cells to be less recognised by T cells by deleting or changing those particular molecules. Moreover, the implanted cells are assisted by the introduction of immunomodulatory molecules, such as HLA-E or CD47, to avoid the action of natural killer cells. These methods greatly increase graft survival. To make the treatment safer, other scientists also include inducible inactivation of so-called suicide genes, which enable the removal of transplanted cells in case they grow abnormally (Ghoneim et al., 2024). These modifications, when combined, have significant positive effects on the potential and viability of stem-cell-based β -cell therapies. The combination of these multi-layered immune protection systems provides engineered β cells with the immunological strength to endure hostile immune systems, which traditionally kill transplanted cells in just a few weeks.

The Reason why Continuous Clinical Research is Required

Despite tremendous advances in genetically modified stem-cell therapies, their widespread use in clinical practice remains a subject of cautious experimentation and extensive analysis. The intricacy of engineering human stem cells requires stringent safety measures, such as tracking of the unwanted genetic alterations, malignancy, and the durability of immune-evasive mechanisms (Zuo et al., 2025). It also has to undergo clinical evaluation to determine whether the modified β cells remain functional in the long term and whether they can effectively control blood glucose. The regulatory factors also influence the evolution of such therapies, as it is necessary to comply with ethical standards and to ensure uniform production and reporting of results. It is thus necessary to conduct further research not only to refine the methods of genetic engineering but also to provide safe, scalable, and repeatable therapeutic solutions for patients with insulin-deficient diabetes.

Conclusion

Genetically engineered stem-cell-based insulin-producing β -cells are an effective and technologically superior solution to the long-term insulin-deficiency problem in diabetes. These engineered cells have the potential to replenish natural glucose-responsive insulin production by circumventing the shortcomings of current treatment options and thus lowering the lifelong costs of exogenous insulin replacement therapy. With the application of improvements to the key transcription factor, CRISPR-based genetic precision, and immunoprotective alterations, researchers can currently produce β cells that are comparatively close to the original ones in terms of functionality and sustainability.

Despite the major advancement, it is also important that clinical research continues to confirm long-term safety, immunogenicity, and the enduring therapeutic efficacy. The ongoing advances in genetic and stem-

cell technology are bringing the discipline a notch closer to the realisation of a dependable curative treatment alternative. Finally, genetically modified stem cells are among the most promising frontiers for transformative diabetes treatment, offering a plausible path to achieving long-term insulin independence.

References

- Ghoneim, M. A., Gabr, M. M., El-Halawani, S. M., & Refaie, A. F. (2024). Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration. *Stem Cell Research & Therapy*, 15(1), 23. <https://doi.org/10.1186/s13287-024-03636-0>
- Jiang, H., & Jiang, F. (2023). Human pluripotent stem cell-derived β cells: Truly immature islet β cells for type 1 diabetes therapy? *World Journal of Stem Cells*, 15(4), 182–195. <https://doi.org/10.4252/wjsc.v15.i4.182>
- Oliveira, S. M. R., Rebocho, A., Ahmadpour, E., Nissapatorn, V., & De Lourdes Pereira, M. (2023). Type 1 Diabetes mellitus: A review on advances and challenges in creating insulin-producing devices. *Micromachines*, 14(1), 151. <https://doi.org/10.3390/mi14010151>
- Vaghari-Tabari, M., Hassanpour, P., Sadeghsoltani, F., Malakoti, F., Alemi, F., Qujeq, D., Asemi, Z., & Yousefi, B. (2022). CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. *Cellular & Molecular Biology Letters*, 27(1), 49. <https://doi.org/10.1186/s11658-022-00348-2>
- Zuo, D., Wang, C., Sang, M., Sun, X., Chen, G., & Ji, K. (2025). Stem cell therapy for diabetes: Advances, prospects, and challenges. *World Journal of Diabetes*, 16(7), 107344. <https://doi.org/10.4239/wjd.v16.i7.107344>